Member access

4-Traders Homepage  >  Shares  >  Xetra  >  TOMORROW FOCUS AG    TFA   DE0005495329

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
01/23/2015 01/26/2015 01/27/2015 01/28/2015 01/29/2015 Date
3.7(c) 3.705(c) 3.73(c) 3.69(c) 3.731(c) Last
23 940 9 885 15 459 5 910 27 174 Volume
+3.64% +0.14% +0.67% -1.07% +1.11% Change
More quotes
Company
Tomorrow Focus AG engages in the development and operation of systems, content, and communication solutions.It operates through the following segments: Transactions, Advertising, Technologies and Holding.The Transactions segment brings together all transaction-based business models including the... 
Sector
Consumer Publishing
Calendar
03/31Earnings Release
More about the company
Surperformance© ratings of TOMORROW FOCUS AG
Trading Rating : Investor Rating :
More Ratings
Chart TOMORROW FOCUS AG
Duration : Period :
TOMORROW FOCUS AG Technical Analysis Chart | TFA | DE0005495329 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 201 M
EBIT 2014 9,39 M
Net income 2014 4,43 M
Debt 2014 23,2 M
Yield 2014 1,03%
Sales 2015 212 M
EBIT 2015 17,5 M
Net income 2015 12,9 M
Debt 2015 17,1 M
Yield 2015 1,90%
PER 2014 106,03
PER 2015 18,42
EV / Sales 2014 1,18x
EV / Sales 2015 1,09x
Capitalization 215 M
More Financials
Latest news on TOMORROW FOCUS AG
2014 TOMORROW FOCUS : sells subsidiary Cellular GmbH in management buy-out deal
2014 TOMORROW FOCUS : sells subsidiary Cellular GmbH in management buy-out deal (DGAP..
2014 TOMORROW FOCUS : records substantial increase in third-quarter revenue with adju..
2014 TOMORROW FOCUS : records substantial increase in third-quarter revenue with adju..
2014TOMORROW FOCUS AG : quaterly earnings release
2014 TOMORROW FOCUS : withdrawal from French travel market
2014 TOMORROW FOCUS : withdrawal from French travel market (DGAP Adhoc)
2014 TOMORROW FOCUS : records significant revenue and earnings growth in the second q..
More news
Sector news Digital Publishing
11:16pDJValeant to Buy Prostate-Cancer Drug From Dendreon
11:06p Valeant to buy Dendreon's prostate cancer vaccine Provenge
10:55pDJValeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon
Plus d'actualités du secteur Digital Publishing


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF